Krill oil composition enriched in LPC-DHA and LPC-EPA
AssigneesAker Biomarine Human Ingredients AS, The Board of Trustees of the University of Illinois
InventorsFinn Myhren, Petter-Arnt Hals, Nils Hoem, Andreas Berg Storsve, Papasani V. Subbaiah, Poorna Yalagala, Sugasini Dhavamani, Leon Tai
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.
Claims17
A method for treating a liver disease selected from the group consisting of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a subject in need thereof comprising:
- administering to the subject in need thereof an effective amount of a pharmaceutical or nutraceutical formulation comprising a lysophosphatidylcholine (LPC) composition comprising a LPC-compound selected from the group consisting of any one of formulas 1 to 8, and any combination thereof, so that the symptoms of the disease or condition are improved, controlled, reduced, or alleviated:
- wherein:
- R1 is OH or —OC(O)(CH2)nCH3;
- R2 is OH or —OC(O)(CH2)nCH3;
- and
- n is 0, 1, or 2;
- and wherein the molar ratio of lysoPC-DHA:lysoPC-EPA is in the range of from 3:1 to 1:5;
- and
- further wherein
- i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA plus the number of moles 2-lysoPC-EPA;
- and
- ii) ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA plus the number of moles 2-lysoPC-DHA.
Dependencies are inferred from the claim text.